Ardsley Advisory Partners LP recently announced the acquisition of new stake in Bioceres Crop Solutions Corp. (NASDAQ:BIOX). The institutional investor has increased its shareholding in the Basic Materials company by 6.02% to 1.71 million shares with purchase of 97071.0 shares. This fresh investment now brings its stake to 2.72% valued currently at $20.58 million. In addition, Uniplan Investment Counsel, Inc. raised its holdings by 34497.0 to 0.32 million shares. And Prince Street Capital Management has lifted its position by 22.45% or 33000.0 shares – to 0.18 million shares.
With over 0.12 million Bioceres Crop Solutions Corp. (BIOX) shares trading Friday and a closing price of $12.11 on the day, the dollar volume was approximately $1.49 million. The shares have shown a positive half year performance of 22.32% and its price on 01/20/23 gained nearly 4.31%. Currently, there are 60.54M common shares owned by the public and among those 23.42M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for BIOX have a consensus price objective of $27.13. The analysts have set the share’s price value over the next 12 months at a high of $30.00 and a low of $22.50. The average price target is 51.83% above its recent price level and an upside to the estimated low will see the stock gain 46.18% over that period. But an upside of 59.63% will see the stock hit the forecast high price target while median target price for the stock is $28.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Bioceres Crop Solutions Corp. are Ballast Small/Mid Cap ETF, Royce Smaller Companies Growth Fu, and PRIMECAP Odyssey Aggressive Growt. Ballast Small/Mid Cap ETF owns 0.12 million shares of the company’s stock, all valued at over $1.4 million. The company bought an additional 1372.0 shares recently to bring their total holdings to about 0.19% of the shares outstanding. Royce Smaller Companies Growth Fu bought 45000.0 shares to see its total holdings expand to 0.11 million shares valued at over $1.36 million and representing 0.18% of the shares outstanding. PRIMECAP Odyssey Aggressive Growt now owns shares totaling to 0.18% of the shares outstanding.
Shares of Bioceres Crop Solutions Corp. (NASDAQ: BIOX) opened at $11.73, up $0.12 from a prior closing price of $11.61. However, the script later moved the day high at 12.68, up 4.31%. The company’s stock has a 5-day price change of -3.04% and -2.96% over the past three months. BIOX shares are trading 0.67% year to date (YTD), with the 12-month market performance down to -13.44% lower. It has a 12-month low price of $9.27 and touched a high of $16.00 over the same period. BIOX has an average intraday trading volume of 83.20K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.73%, -4.20%, and -5.36% respectively.
Institutional ownership of Bioceres Crop Solutions Corp. (NASDAQ: BIOX) shares accounts for 23.90% of the company’s 60.54M shares outstanding. Mutual fund holders own 1.62%, while other institutional holders and individual stakeholders account for 22.36% and — respectively.
It has a market capitalization of $729.14M and a beta (3y monthly) value of 0.37. The earnings-per-share (ttm) stands at -$0.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.24% over the week and 4.26% over the month.
Analysts forecast that Bioceres Crop Solutions Corp. (BIOX) will achieve an EPS of $0.05 for the current quarter, $0.19 for the next quarter and $0.88 for 2024. The lowest estimate earnings-per-share for the quarter is $0.01 while analysts give the company a high EPS estimate of $0.09. Comparatively, EPS for the current quarter was $0.02 a year ago. Earnings per share for the fiscal year are expected to increase by 2.80%, and 164.24% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Bioceres Crop Solutions Corp. (BIOX) as a “Strong Buy” at a consensus score of 1.70. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BIOX, a number of firms have released research notes about the stock. Canaccord Genuity stated their Buy rating for the stock in a research note on September 30, 2022, with the firm’s price target at $22.50. ROTH Capital coverage for the Bioceres Crop Solutions Corp. (BIOX) stock in a research note released on October 08, 2021 offered a Buy rating with a price target of $21.